World Health Organization Raises Alert Over Acute Lack of Obesity Injections
Less than 10% of individuals who could benefit from weight-loss injections such as Wegovy are able to get them, caution the World Health Organization as it issues its initial recommendations on the medications.
With in excess of 1,000,000,000 individuals worldwide now obese, it is calling for increased and just availability to GLP-1 medication.
Per estimates, over two billion could be obese by 2030 unless action is taken.
"The latest guidelines acknowledges that excess weight is a long-term condition that can be addressed with thorough and lifelong support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are major hurdles to universal access to the jabs that can help people shift considerable weight, notes the body.
Weight-Loss Drug Scarcity
Even under the current most favorable scenario, the manufacturing of these medications might only reach around 100 million people – fewer than 10% of eligible patients, according to the health organization.
The recommendation urges governments and firms to expand access, by approaches like voluntary licensing.
A patent on the active ingredient – the main component of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026.
The Way Obesity Injections Function
These medications imitate a body's own hormone to reduce digestion speed, reduce hunger and increase satiety so people eat less.
People usually begin shedding pounds in the initial weeks of beginning the weekly injections.
Evidence points to people may see weight return a year later of discontinuing the drug, when their usual food cravings come back.
To be above a healthy weight raises your risk for contracting diseases, including type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight concerns individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.
